Business Development for the Biotechnology and by Martin Austin

By Martin Austin

Company improvement within the Biotechnology and pharmaceutical industries bills for over $5 billion in licensing deal price in keeping with 12 months and lots more and plenty greater than that during the worth of mergers and acquisitions. Transactions variety from licences to patented educational examine, to product advancements as licences, joint ventures and acquisition of highbrow estate rights, and directly to collaborations in improvement and advertising and marketing, in the community or around the globe. Asset revenues, mergers and company take-overs also are part of the company improvement remit. The scope of the task will be large, spanning the life-cycle of goods from the earliest degrees of study to the disposal of residual advertising rights, related to felony regulatory production, medical improvement, revenues and advertising and marketing and fiscal aspects.The wisdom and talents required of practitioners has to be equally wide, but the supply of knowledge for constructing a profession in company improvement is sparse. Martin Austin's hugely useful advisor spans the total strategy and is predicated on his 30 years of expertise within the and the well-established education programme that he has built and gives you to pharmaceutical executives from internationally.

Show description

Read or Download Business Development for the Biotechnology and Pharmaceutical Industry PDF

Similar pharmacy books

Capillary Electrophoresis in Chiral Analysis

Capillary Electrophoresis in Chiral research Bezhan Chankvetadze Tbilisi nation college, Republic of Georgia the appliance of capillary electrophoresis (CE) to the sphere of chiral research has exploded lately. the benefits of capillary electrophoresis - super excessive height potency, first-class compatibility with organic samples, brief research time, simplicity, versatility and occasional rate - are ideal for the exact size of optical purity, more and more vital within the regulation-ruled pharmaceutical undefined.

Recent Advances in Redox Active Plant and Microbial Products: From Basic Chemistry to Widespread Applications in Medicine and Agriculture

Nature endows us with a treasure chest of eco-friendly Gold jam-packed with extraordinary ‘redox-active’ elements which intrude with a variety of organic tactics in our personal physique, in animals, micro organism, fungi and crops. when such typical items are throughout and likewise in us, we nonetheless don't totally know how those compounds really paintings.

Oxford Handbook of Clinical Pharmacy

Now absolutely up-to-date for a moment variation, the Oxford guide of scientific Pharmacy is still the indispensible advisor to medical pharmacy, delivering all of the details wanted for practicing and scholar pharmacists. featuring convenient useful information in a quick-reference, bullet-point layout, it is going to offer the data and self assurance you must offer a scientific pharmacy carrier.

Handbook of polymers for pharmaceutical technologies. Volume 4, Bioactive and compatible synthetic/hybrid polymers

Polymers are probably the most attention-grabbing fabrics of the current period discovering their purposes in virtually each facets of existence. Polymers are both at once on hand in nature or are chemically synthesized and used based upon the certain purposes. Advances in polymer technological know-how and the creation of recent polymers have ended in the numerous improvement of polymers with specific houses.

Additional resources for Business Development for the Biotechnology and Pharmaceutical Industry

Sample text

This is a simple but effective analysis tool at a high level for mature companies with a broad portfolio. It is less useful in the context of a younger company where the portfolio will tend to fall into one or two categories, leaving liĴle strategic choice as to where to direct investment. The analysis is also restricted in its utility to marketed products. This is because development-level products and research projects have no performance to measure, only forecasts, and, understandably, the forecasts for all such projects will be good.

Today, despite new and massively automated screening techniques, there has been no significant increase in the number of candidates with the potential to become a drug. 4 Discovery success 22 Phase III Singles P L A N N I N G T H E P O RT F O L I O drug. The confluence of aĴributes which constitute a molecule that is both safe and efficacious is a rare event. Rarer still is a molecule which has these characteristics and will prove beĴer than existing therapies. Furthermore the advances in diagnostic analytical techniques have revealed a great many more adverse events which compounds in development must avoid.

For innovative, research-based companies, the sophistication of the generic drug manufacturing companies has had serious consequences on revenue. Twenty years ago, when a large product lost its patent protection the main erosion of market share that it suffered would take 2 to 3 years. Now, the aggressive pursuit of abbreviated new drug applications by generic companies both in the USA and in the rest of the world can mean a major product will now lose 80 per cent of its worldwide market share in less than 3 months.

Download PDF sample

Rated 4.75 of 5 – based on 14 votes